OncLive TV

Dr. Stevenson on Potential of Immunotherapy in Squamous NSCLC

September 8th 2016

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Dr. Decker on Stereotactic Body Radiation Therapy in Lung Cancer

September 8th 2016

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses stereotactic body radiation therapy (SBRT) as a treatment for patients with lung cancer.

Dr. Strosberg on the Results of the NETTER-1 Trial

September 8th 2016

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.

Dr. Donnellan on TFR in Patients With CML Treated With Nilotinib

September 7th 2016

William B. Donnellan, MD, investigator, Hematologic Malignancies, principal investigator, Sarah Cannon Research Institute, discusses preliminary results of the ENESTop study, which looked at treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase who were treated with second-line nilotinib (Tasigna).

Dr. Esteva on Clinical Trial Design of Trastuzumab Biosimilar in HER2+ Breast Cancer

September 7th 2016

Francisco J. Esteva, MD, PhD, medical oncologist, New York Langone Medical Center, discusses the importance of having a clinical trial of the trastuzumab (Herceptin) biosimilar MYL-1401O for patients with HER2-positive breast cancer.

Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCC

September 7th 2016

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).

Dr. Randolph on Evolving Role of Surgery for Patients With Thyroid Cancer

September 6th 2016

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, discusses how the role of surgery has evolved for patients with thyroid cancer.

Dr. Brown on Lessons Learned From RESONATE-2 Trial for CLL

September 6th 2016

Jennifer Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the lessons oncologists have learned from the RESONATE-2 trial, which showed a benefit with ibrutinib (Imbruvica) over chlorambucil in patients with chronic lymphocytic leukemia (CLL).

Dr. Levine on Evolving Treatment Options for Patients With mCRPC

September 5th 2016

Richard M. Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer.

Dr. Sunil Verma on Treatment for Early HER2+ Breast Cancer

September 2nd 2016

Dr. Leslie M. Randall on Early BRCA Testing in Ovarian Cancer

September 2nd 2016

Dr. Joshua M. Bauml on the Impact of Pembrolizumab in Head and Neck Cancer

September 2nd 2016

Dr. Johnstone on Immediate Salvage Therapy for Prostate Cancer

September 2nd 2016

Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

September 2nd 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCC

September 1st 2016

Michael L. Blute, MD, chair of Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Sharma on Tolerability of SIRT in Patients With CRC

September 1st 2016

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) when added to chemotherapy for patients with colorectal cancer (CRC) that has metastasized to the liver.

Dr. Areej El-Jawahri on the Impact of Palliative Care

September 1st 2016

Dr. Barbara J. Gitlitz on Why PD-L1 is Not a Good Biomarker for Immunotherapy in Lung Cancer

September 1st 2016

Dr. Kathy S. Albain on Breast Cancer Risk After 5 Years of Tamoxifen

September 1st 2016

Dr. White on Relationship Between Multigene Assays and RT in Breast Cancer

September 1st 2016

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the relationship between multigene assays and radiation therapy in patients with breast cancer.